Feeding your demons practice: The Feeding Your Demons (FYD) is a contemplative practice based on the Tibetan Buddhist tradition, adapted in a secular form. The intervention is online and lasts a total of 8 weeks. During this period, participants will engage in weekly home practice of the FYD method using guided audio. The intervention includes 3 expert-facilitated sessions: an initial individual session, a group session at week 4, and a final group session at week 8.
Mindfulness practice: The control group will undergo an online mindfulness meditation intervention, lasting a total of 8 weeks. It includes 3 expert-facilitated sessions: an initial individual session, a group session at week 4, and a final group session at week 8. Participants will engage in weekly home practice of mindfulness meditation using guided audio.
Study summary
This randomized controlled trial aims to evaluate the effectiveness of a contemplative practice called Feeding Your Demons (FYD), based on a secular adaptation of Tibetan Buddhism, in improving psychological well-being, body image, body acceptance, compassion, and self-deconstruction in adult women. Participants will be randomly assigned to either FYD or an active control group practicing mindfulness meditation. Psychological variables will be assessed before and after the intervention, and at a six-month follow-up. Additionally, a qualitative exploration will be conducted through interviews with a subgroup of participants.
Eligibility
Sex
FEMALE
Min age
30 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria:
* Sex assigned female at birth and self-identifies as a woman
* Aged between 30 and 60 years
* Spanish nationality, or residency in Spain for more than 5 years
* Fluent in Spanish
* At least one month of experience with meditation or mindfulness practices, with a regular practice of more than 15 minutes per session
* Provides informed consent
Exclusion Criteria:
* Indicators of eating disorders (ED) or mental health deterioration, determined by the following cut-off points: SCOFF ≥ 2 and PHQ-9 ≥ 10
* Formal diagnosis of an eating disorder or any psychiatric condition
* Substance use disorder
* History of neurological disease diagnosis
* Participant's decision to withdraw from the study at any point
Primary outcome measure(s)
Delusion of Me Index (DoM) — From baseline to 6-month follow-up The primary outcome will be the change in self-related perception from baseline to 6-month follow-up after randomisation. This includes changes in acceptance, decentering, and non-attachment. Participants will complete this measure at three time points: baseline (week 0), post-intervention (week 8), and 6-month follow-up.
Nondual Awareness Dimensional Assessment (NADA) — From baseline to 6-month follow-up The primary outcome will be the change in self-related perception from baseline to 6-month follow-up after randomisation. This outcome includes changes in nondual awareness. Participants will complete this measure at three time points: baseline (week 0), post-intervention (week 8), and 6-month follow-up.
Body Appreciation Scale-2 (BAS-2) — From baseline to 6-month follow-up The second primary outcome will be the change in body image from baseline to 6-month follow-up after randomisation. This includes improvements in positive body image, specifically body appreciation. Participants will complete this measure at three time points: baseline (week 0), post-intervention (week 8), and 6-month follow-up.
Body Shape Questionnaire-10 (BSQ-10) — From baseline to 6-month follow-up The second primary outcome will be the change in body image from baseline to 6-month follow-up after randomisation. This includes reductions in negative body image, specifically body dissatisfaction. Participants will complete this measure at three time points: baseline (week 0), post-intervention (week 8), and 6-month follow-up.
Trial sites (2)
Facility
City
Region
Status
Department of Psychiatry. Miguel Servet University Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.